Treatment News : Blood Thinner Reduces Liver Vein Blood Clots, Protects Liver Functioning in People With Cirrhosis

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » November 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


November 17, 2011

Blood Thinner Reduces Liver Vein Blood Clots, Protects Liver Functioning in People With Cirrhosis

People with liver cirrhosis may benefit from daily therapy with a blood thinner to prevent portal vein thrombosis (PVT), a potentially serious and life-threatening complication, according to an important study presented by Italian researchers at the 62nd annual meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco. Using the injectable agent enoxaparin—sold as Lovenox in the United States—for 12 months not only reduced the risk of PVT by nearly 80 percent, but also reduced the risk of decompensated liver disease.

The portal vein is a very large vessel in the abdomen responsible for carrying blood from the gastrointestinal tract and spleen to the liver. People with serious liver disease, such as hepatitis B- or hepatitis C-associated cirrhosis, are prone to developing PVTs—blood clots in their portal veins. When the vein is blocked, it can cause a buildup of pressure, or portal hypertension, which can lead to life-threatening disease.

According to Erica Villa, MD, of the University of Modena and Reggio Emilia in Modena, Italy, and her colleagues, PVT is a frequent complication of advanced cirrhosis, occurring in about 8 percent to 25 percent of patients. Though blood thinners to prevent PVT have shown to be beneficial in retrospective analyses—studies that look back on patients’ experiences with the drugs—data from prospective evaluations, notably clinical trials designed to specifically look at the safety and efficacy of anticoagulant therapy, have been scarce.

Enoxaparin, approved by the U.S. Food and Drug Administration for the prevention of deep vein thrombosis (DVT)—blood clots in the leg that can lead to pulmonary artery blockage—was therefore put to the test by Villa’s team in a study of 70 people with advanced liver cirrhosis. Patients were randomly allotted to receive either 4,000 international units (IU) enoxaparin or placebo for 12 months and were then followed, off treatment, for another 12 months.

The study’s primary goal was to see if enoxaparin reduced the incidence of PVT. Villa’s group also wanted to find out if treatment slowed or prevented decompensation—a sign of liver failure—and improved survival. As for safety measurements, the researchers also set out to determine if enoxaparin treatment was associated with excessive bleeding, a serious risk of anticoagulant therapy.

According to Villa’s report, six of the 36 patients (16.7 percent) who received placebo, compared with no patients who received enoxaparin, developed either a complete or partial portal vein blockage while on treatment during the first 12 months of the study. This difference between the two groups was statistically significant, meaning it was too great to have occurred by chance.

During the 12-month follow-up period, six additional blood clots occurred: three among those in the placebo group and three among those who originally received enoxaparin. These blood clots typically occurred within two to six months after enoxaparin was discontinued.

Liver decompensation was significantly more likely to occur among those who received placebo in the study. Nineteen (52.7 percent) in the placebo group, compared with four (11.7 percent) in the enoxaparin group, had signs of liver failure during treatment. Even after treatment was stopped, rates of decompensation remained higher among those who received placebo, compared with those who received enoxaparin.

Villa noted that survival was also better among those who received enoxaparin compared with those who received placebo.

In addition, Villa said, enoxaparin treatment was well tolerated. There were no reports of excessive bleeding among any patients in the study.

“In this prospective randomized controlled study in advanced stage cirrhotics,” Villa’s group concluded, “enoxaparin was shown to be safe and effective in preventing PVT but, most importantly, was associated with greatly reduced occurrence of decompensation both during the active period of treatment and in the follow-up period.”

Search: portal vein thrombosis, pvt, enoxaparin, Lovenox, Sanofi, blood clots, anticoagulant, blood thinner, portal hypertension, decompensation, survival, cirrhosis, hepatitis, Villa, AASLD

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.